Reviewing Enlivex Therapeutics (NASDAQ:ENLV) and Mannatech (NASDAQ:MTEX)

Mannatech (NASDAQ:MTEX) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations and institutional ownership.

Volatility & Risk

Mannatech has a beta of 0.72, meaning that its stock price is 28% less volatile than the S&P 500. Comparatively, Enlivex Therapeutics has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500.

Profitability

This table compares Mannatech and Enlivex Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mannatech	-11.97%	-2,383.34%	-40.24%
Enlivex Therapeutics	N/A	248.08%	206.39%

Institutional and Insider Ownership

13.0% of Mannatech shares are owned by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are owned by institutional investors. 47.5% of Mannatech shares are owned by insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Mannatech and Enlivex Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mannatech	$108.04 million	0.08	-$15.21 million	($6.71)	-0.67
Enlivex Therapeutics	N/A	N/A	$1.24 billion	($8.25)	-0.51

Enlivex Therapeutics has lower revenue, but higher earnings than Mannatech. Mannatech is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Mannatech and Enlivex Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mannatech	1	0	0	0	1.00
Enlivex Therapeutics	1	1	1	1	2.50

Enlivex Therapeutics has a consensus price target of $247.50, suggesting a potential upside of 5,792.86%. Given Enlivex Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Enlivex Therapeutics is more favorable than Mannatech.

Summary

Enlivex Therapeutics beats Mannatech on 10 of the 14 factors compared between the two stocks.

About Mannatech

Mannatech, Incorporated operates as a health and wellness company in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management and fitness products. It primarily sells its products directly, as well as through e-commerce and network marketing channels. Mannatech, Incorporated was incorporated in 1993 and is headquartered in Flower Mound, Texas.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.